Bio-Rad Laboratories, Inc. (BIO) Stock: Price, Forecast & Analyst Target
Bio-Rad Laboratories, Inc. (BIO) — MoonshotScore 77/100 (Strong band), calculated Nov 18, 2026. Price $370.17 (+3.34%), as of the Nov 18, 2026 trading session; market cap $9.95B. Expected results Feb 11, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 5.98× (cash as of Sep 30, 2026) · expected results Feb 11, 2027
Bio-Rad Laboratories, Inc. · BIO · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-13: Bio-Rad sells research reagents, laboratory instruments, diagnostic test systems, quality controls and related software to scientific and clinical laboratories; it is not simply a medical-device manufacturer. The case now rests on whether improving operating performance can persist while management still expects subdued demand across Life Science and Clinical Diagnostics.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Bio-Rad Laboratories (BIO)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and a strong balance sheet, though growth is only middling; the market is already moving on it. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $653M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 3.81 · Piotroski F 5
Helping: business quality, balance-sheet strength, an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 81 | Exceptional | |
| 80 | Exceptional | |
| 80 | Exceptional | |
| 80 | Exceptional | |
| 77 | Strong | |
| 77 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $370.17 | |
| Change on the day | +3.34% | |
| 52-week range | $236.73–$396.23 | |
| Market capitalisation | $9.95B | — |
| Price / earnings (trailing) | 9.39 | |
| Shares traded on the day | 460.5K | |
| Beta (volatility vs the S&P 500) | 1.06 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We expect full year growth to be approximately at the midpoint of this range. We expect Life Science segments currency-neutral revenue growth to be between minus 3% and minus 1% and the Clinical Diagnostics segment's currency-neutral revenue growth to be between minus 3% and plus 1%.
Roop Lakkaraju · Statement from
We expect a sequential revenue ramp from Q3 to Q4, up 5% to 6% on a reported basis, in line with our typical seasonality.
Roop Lakkaraju · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Bio-Rad Laboratories (BIO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Bio-Rad Laboratories (BIO), and what does it report?
Short answer · as of
Life Science serves academic, government, biotechnology, pharmaceutical and food-testing customers with tools used in research, biopharmaceutical production and analytical workflows.
Research dated 2026-09-13.
Clinical Diagnostics supplies hospital, reference, newborn-screening, physician-office and transfusion laboratories with test systems, reagents, informatics and quality controls.
Clinical Diagnostics contributes more revenue than Life Science, so reported sales measure a blend of research spending and routine clinical-laboratory demand. That mix makes Bio-Rad different from a pure equipment vendor: consumables, instruments and software all sit inside the reported business.
What do the latest results show for Bio-Rad Laboratories (BIO)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $653M.
Research dated 2026-09-13.
Revenue rebounded from the preceding period and returned close to its prior comparable level. Gross profit increased, operating profit rose sharply, and reported revenue and earnings exceeded market estimates in the latest release.
Management nevertheless reaffirmed an outlook ranging from contraction to only slight growth, with pressure contemplated in each operating segment. A recent filing also identifies costs associated with exit or disposal activities, making execution around those actions relevant to the operating improvement.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $656.40M Sep 30, 2026
- Latest quarter · R&D
- $71.40M Sep 30, 2026
- Latest quarter · SG&A
- $257.10M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$49.70M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $656.40M | $71.40M | $257.10M | −$49.70M |
| Jun 30, 2026 | $651.00M | $61.20M | $212.00M | $72.60M |
| Mar 31, 2026 | $592.10M | $62.90M | $212.40M | $34.10M |
| Dec 31, 2025 | $693.20M | $65.70M | $216.60M | $61.90M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $656.40M Nov 4, 2026
- Latest report · revenue estimate
- $649.94M Nov 4, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 4, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 4, 2026 | $656.40M | $649.94M | $2.6500 | $2.2300 |
| Aug 4, 2026 | $651.00M | $623.99M | $2.6200 | $1.7500 |
| Apr 30, 2026 | $592.10M | $589.91M | $1.8900 | $1.9700 |
| Feb 12, 2026 | $693.20M | $688.81M | $2.5100 | $2.5700 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $653M | -$342M | -$12.70 (diluted) |
| Q4 FY2025 | $693M | $720M | $26.65 (diluted) |
| Q1 FY2026 | $592M | -$527M | -$19.55 (diluted) |
| Q2 FY2026 | $651M | $371M | $13.85 (diluted) |
What are the financial strengths and risks for Bio-Rad Laboratories (BIO)?
Short answer
Cash and short-term investments were $1.66B at the Sep 30, 2026 balance-sheet date. Operating cash flow was $96.40M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Bio-Rad's financial flexibility is substantial: cash and short-term investments exceed debt, while the broader pool including long-term investments exceeds total liabilities. Cash and short-term holdings have remained broadly stable across the reported window, and operating cash flow has stayed positive after capital spending.
The principal analytical risk is earnings quality rather than immediate liquidity. Operating profit remained positive while net results swung between large gains and losses, so headline net income can diverge sharply from the performance of the laboratory-products business. The trailing valuation therefore demands more than balance-sheet strength; it requires durable operating returns that are currently modest relative to equity and assets.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $96.40M Sep 30, 2026
- Previous quarter · operating cash flow
- $98.70M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $96.40M | −$31.20M |
| Jun 30, 2026 | $98.70M | −$32.00M |
| Mar 31, 2026 | $108.10M | −$30.00M |
| Dec 31, 2025 | $164.90M | −$45.80M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Bio-Rad Laboratories (BIO)?
Short answer · as of
The next earnings report is expected on Feb 11, 2027.
Research dated 2026-09-13.
Watch whether revenue holds near the latest level while operating profit preserves its recent improvement. Segment performance matters: Life Science must contain the decline embedded in management's outlook, while Clinical Diagnostics needs to remain the steadier revenue base.
Cash conversion should corroborate any earnings progress through operating cash flow after capital spending. The scheduled earnings release also provides a direct test of management's reaffirmed margin framework and of analyst expectations for gradual revenue and earnings expansion beyond the current year.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We expect full year non-GAAP gross margin to be in the upper half of the guidance range of between 53% and 54%.
Roop Lakkaraju ·
We expect full year non-GAAP operating margin to be in the upper half of the guidance range of between 10% and 12%.
Roop Lakkaraju ·
What the records here don't tell us
- The newest quarter held here (Q3 FY2025) was filed Oct 29, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Bio-Rad Laboratories compare with its peers?
Short answer
Bio-Rad Laboratories's score ranks 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Bio-Rad combines research tools and clinical diagnostics under the same company, whereas many comparable businesses lean primarily toward laboratory research, diagnostic testing or medical equipment. Its larger Clinical Diagnostics operation supplies a stabilizing source of laboratory demand, while Life Science adds exposure to research budgets, biotechnology activity, biopharmaceutical production and food testing.
Another distinguishing feature is the investment-heavy balance sheet alongside comparatively modest operating returns. That combination can make reported net income and conventional earnings valuation less representative of the underlying operating business than revenue, operating profit and cash generation.
| Company | Price | Market value | Score |
|---|---|---|---|
| $70.53 Nov 18, 2026 | $9.34B | 94 5-pillar Nov 18, 2026 | |
| $320.50 Nov 18, 2026 | $12.6B | 92 5-pillar Nov 18, 2026 | |
| $94.54 Nov 18, 2026 | $5.21B | 88 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $139.98 Nov 18, 2026 | $9.71B | 85 5-pillar Nov 18, 2026 | |
| $30.32 Nov 18, 2026 | $12.7B | 84 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $103.32 Nov 18, 2026 | $19.6B | 79 5-pillar Nov 18, 2026 | |
| $29.81 Nov 18, 2026 | $29.1B | 78 5-pillar Nov 18, 2026 | |
| Bio-Rad Laboratories (BIO) — this page | $370.17 | $9.95B | 77 |
| $161.75 Nov 18, 2026 | $10.2B | 76 5-pillar Nov 18, 2026 | |
| $126.97 Nov 18, 2026 | $4.32B | 68 5-pillar Nov 18, 2026 | |
| $63.26 Nov 18, 2026 | $9.66B | 59 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $310.00 – $390.00
- Consensus target
- $350.00
- Median target
- $350.00
Consensus record · Captured .
Measured against a quoted price of $370.17 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 10, 2026
- Transactions
- 60
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 3
- Other transactions
- 57
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 70.9% Period end Sep 30, 2026
- Previous quarter · ownership
- 73.3% Prior to period end Sep 30, 2026
- Reporting holders
- 423 Period end Sep 30, 2026
- Previous quarter · holders
- 409 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| First Eagle Investment Management, LLC | 2,455,580 |
| Blackrock, INC. | 1,740,336 |
| Dimensional Fund Advisors LP | 885,977 |
| Vanguard Capital Management LLC | 827,202 |
| Vanguard Portfolio Management LLC | 811,564 |
Tracked investors
Which of the 16 named investors we follow held BIO in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BIO in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Bio-Rad Laboratories (BIO)?
- 2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
- BIO-key Q3 Software License Fees Grew 39%, Its Third Consecutive Quarter of Double-Digit Growth, Driven Primarily by Momentum in the Middle East and Europe; Hosts Call Today at 10am ET
- BIO GREEN MED SOLUTION REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
BIO Healthcare Stock FAQ
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why does Bio-Rad sell more than medical devices?
Bio-Rad supplies reagents, diagnostic kits, quality controls, laboratory instruments and informatics as well as equipment. Demand therefore comes from recurring laboratory workflows and research activity, not solely from purchases of capital devices.
Why can Bio-Rad's net income diverge from operating profit?
Operating profit remained positive across the reported periods while net results moved between substantial gains and losses. Revenue, operating profit and cash flow consequently provide a cleaner view of laboratory-product performance than net income alone.
Is Clinical Diagnostics larger than Bio-Rad's Life Science business?
Clinical Diagnostics contributes more revenue than Life Science. Its hospital, reference, screening and transfusion laboratory customers give Bio-Rad a demand base distinct from the academic, biotechnology and pharmaceutical customers served by Life Science.
What would confirm Bio-Rad's reaffirmed margin framework?
Confirmation would require operating profitability to hold above its trailing level while revenue remains within management's subdued range. Continued cash generation after capital spending would strengthen that evidence.
What is the BIO stock price today?
The last price recorded for Bio-Rad Laboratories, Inc. (BIO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BIO price target?
The analyst consensus price target for Bio-Rad Laboratories, Inc. (BIO), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 82 figures on this page — 2 from SEC filings and earnings calls, 74 from Financial Modeling Prep (FMP), 2 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com